You are currently viewing a new version of our website. To view the old version click .
  • Tracked forImpact Factor
  • Indexed inScopus
  • 22 daysTime to First Decision

Pharmacoepidemiology, Volume 4, Issue 2

June 2025 - 6 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (6)

  • Article
  • Open Access
967 Views
15 Pages

Objectives: This study aimed to assess the concordance between depression and anxiety case definitions derived from algorithms based on medico-administrative data and structured interviews aligned with the fourth edition of the Diagnostic and Statist...

  • Brief Report
  • Open Access
1,044 Views
6 Pages

Treating Opioid Use Disorder on the Inpatient Psychiatric Unit: A Novel Buprenorphine Consultation Service

  • Sean T. Lynch,
  • Victor Gordillo,
  • Ashley Sacks,
  • Emily Groenendaal,
  • Lidia Klepacz,
  • Eldene Towey and
  • Stephen J. Ferrando

Background: Opioid Use Disorder (OUD) has claimed the lives of many Americans, with rates of overdose steadily rising over the past decade. Despite having highly effective medications to treat this condition, many providers still hesitate to prescrib...

  • Article
  • Open Access
1,060 Views
18 Pages

Evaluation of Screening Tool of Older People’s Prescriptions (STOPP) Criteria in an Urban Cohort of Older People with HIV

  • Lauren F. O’Connor,
  • Jenna B. Resnik,
  • Sam Simmens,
  • Vinay Bhandaru,
  • Debra Benator,
  • La’Marcus Wingate,
  • Amanda D. Castel and
  • Anne K. Monroe

Background: The validated Screening Tool of Older People’s Prescriptions (STOPP) identifies potentially inappropriate prescribing (PIP)—treatments where potential risk outweighs potential benefit. STOPP is particularly important for peopl...

  • Article
  • Open Access
1 Citations
2,099 Views
12 Pages

Background: Incretin mimetics, including glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonist) and dipeptidyl peptidase-4 (DPP-4) inhibitors, have been increasingly utilized for glycemic control in patients with type 2 diabetes (T2D). St...

  • Article
  • Open Access
1,138 Views
11 Pages

Objective: The aim of this study was to investigate a possible relationship between the time to onset (TTO) of adverse events following immunization (AEFIs) and recall bias and to compare it between AEFIs of COVID-19 vaccines reported though the spon...

  • Article
  • Open Access
1 Citations
2,569 Views
10 Pages

Background/Objectives: Controversy exists over the use of passive reporting systems, especially the Vaccine Adverse Event Reporting System, in risk assessment. One limitation of these systems is that adverse event (AE) reporting rates cannot be calcu...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Pharmacoepidemiology - ISSN 2813-0618